KLRC2 and gastric cancer: For example, gastric cancer cells and many immune cell subtypes can interact with cytotoxic/exhausted CD8+ T cells and/or NK cells via HLA-E-KLRC1/KLRC2, suggesting that the anti-KLRC1 antibody may be a potential therapeutic option in gastric cancer [94].